Hyperkalemia News and Research

RSS
Caution advised with succinylcholine in critically ill

Caution advised with succinylcholine in critically ill

Researchers publish first detailed figures that show risk of Rasilez and ACE inhibitors or ARBs

Researchers publish first detailed figures that show risk of Rasilez and ACE inhibitors or ARBs

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

U-M Professor to review data from three prominent studies on heart failure

U-M Professor to review data from three prominent studies on heart failure

New clinical data on Bristol-Myers Squibb's NULOJIX to be presented at ESOT 2011 congress

New clinical data on Bristol-Myers Squibb's NULOJIX to be presented at ESOT 2011 congress

Infants treated with certain HIV medication more likely to experience adrenal dysfunction

Infants treated with certain HIV medication more likely to experience adrenal dysfunction

Sorbent expands $36M Series B financing

Sorbent expands $36M Series B financing

Relypsa initiates dosing in RLY5016 Phase 2b trial for hyperkalemia in diabetic nephropathy and CKD patients

Relypsa initiates dosing in RLY5016 Phase 2b trial for hyperkalemia in diabetic nephropathy and CKD patients

FDA approves NULOJIX

FDA approves NULOJIX

Positive results from Relypsa RLY5016 Phase 2 trial to be presented at American Society of Hypertension meeting

Positive results from Relypsa RLY5016 Phase 2 trial to be presented at American Society of Hypertension meeting

ACE, ARB combination therapy may increase risk of kidney failure, death

ACE, ARB combination therapy may increase risk of kidney failure, death

FDA approves Novartis' Amturnide for treatment of high blood pressure

FDA approves Novartis' Amturnide for treatment of high blood pressure

Relypsa announces positive results from Phase 2 clinical trial of RLY5016

Relypsa announces positive results from Phase 2 clinical trial of RLY5016

Relypsa completes $70M Series B financing

Relypsa completes $70M Series B financing

RLY5016 potassium binder helps to regulate hyperkalemia in heart failure patients

RLY5016 potassium binder helps to regulate hyperkalemia in heart failure patients

Patients receiving TMP-SMX antibiotics are more likely to develop hyperkalemia: Study

Patients receiving TMP-SMX antibiotics are more likely to develop hyperkalemia: Study

Relypsa commences enrollment for RLY5016 Phase 2 study in heart failure patients with chronic kidney disease

Relypsa commences enrollment for RLY5016 Phase 2 study in heart failure patients with chronic kidney disease

Pfizer plans recruitment halt to EMPHASIS-HF trial

Pfizer plans recruitment halt to EMPHASIS-HF trial

Review suggests ion exchange resins are not effective for hyperkalemia

Review suggests ion exchange resins are not effective for hyperkalemia

New molecular pathway for preventing potassium from being excreted normally through kidney identified

New molecular pathway for preventing potassium from being excreted normally through kidney identified